AcelRx Pharmaceuticals Inc logo

AcelRx Pharmaceuticals Inc Investor Relations Material

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The Company's lead product candidate is DSUVIA™ (sufentanil sublingual tablet, 30 mcg) which has completed Phase 3 trials. The Company believes that DSUVIA is a potential first-in-class non-invasive treatment option that can deliver rapid relief to patients suffering from moderate to severe acute pain

Upcoming events for

Q4 20222023-03-13

Latest company events

Ticker symbol



United States of America

Dig deeper into the AcelRx Pharmaceuticals Inc fundamentals on Quartr.

  • Conference calls from all over the world
  • Search for anything across all transcripts
  • Consensus estimates
  • Comprehensive financial data
  • Read the transcripts or scroll the deck
  • Slide decks and earnings reports
App store link
Android play link
Quartr app screenshot